Abridged Prescribing Information:

Active Ingredient ZEVERT MD is mouth dissolving tablet contains Betahistine Hydrochloride 8mg, 16 mg, 24 mg

ZEVERT SR is Sustained release tablet contains Betahistine Hydrochloride 12 mg, 24 mg

Indication: ZEVERT tablets are indicated in the treatment of vertigo, tinnitus and hearing loss associated with Ménière's syndrome. **Dosage & Administration**: **Adults (including the elderly):** Initially betahistine is given in a dose of 16 mg three times daily, taken preferably with meals. Maintenance doses are generally in the range of 24-48mg daily. ZEVERT MD tablets are administered three times a day, after meals. ZEVERT SR tablets are given twice a day, after meals. **Contraindication:** Avoid giving ZEVERT tablets to patients with known hypersensitivity to betahistine or to any other ingredient of the product. Also, avoid administration in patients with pheochromocytoma**. Warnings & Precautions:** Caution is advised in patients with a history of peptic ulcer. Clinical intolerance to betahistine hydrochloride in bronchial asthma patients has been shown in relatively few patients and therefore caution should be exercised when administering betahistine to patients with bronchial asthma. Lactose content of the product may render it unsuitable for administration in patients with lactase insufficiency, galactosemia or glucose/galactose malabsorption syndrome. It is also considered unsafe in patients with porphyria. **Pregnancy:** High dosage animal studies have shown no teratogenic properties, but the usual precautions should be observed when administering betahistine hydrochloride to patients during pregnancy. **Adverse Reactions:** Relatively few undesirable effects have been reported. These include gastro-intestinal upset (including dyspepsia), headache, skin rash and pruritus**. Overdose:** No specific antidote. Gastric lavage and symptomatic treatment is recommended.

(For details, please refer full prescribing information)

Version date: 03/03/2023. If you require any further information, please reply us on

productqueries@intaspharma.com